Results 11 to 20 of about 104,183 (265)

Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance

Cell Death and Disease, 2022
Hypoxia-induced cisplatin resistance is a major challenge during non-small cell lung cancer (NSCLC) treatment. Based on previous studies, we further explored the effect of eukaryotic initiation factor 5A2 (eIF5A2) in hypoxia-induced cisplatin resistance.
Guodong Xu, Hang Chen, Shibo Wu, Jiabin Chen, Shufen Zhang, Guofeng Shao, Lebo Sun, Yinyu Mu, Kaitai Liu, Qiaoling Pan, Ni Li, Xiaoxia An, Shuang Lin, Wei Chen   +13 more
doaj   +1 more source

Pulling a MAST1 on Cisplatin Resistance [PDF]

Cancer Cell, 2018
In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.
Ankita B, Jaykumar, Aroon S, Karra, Melanie H, Cobb   +2 more
openaire   +2 more sources

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC

PeerJ, 2021
Backgrounds Cancer cell resistance to chemotherapy drugs such as Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin, and 5-fluorouracil account for the main reason of chemotherapy failure for HCC patients, especially for those with advanced HCC or metastasis patients.
Tang, Zuxiong, He, Jun, Zou, Jiayue, Yu, Shufei, Sun, Xiaoming, Qin, Lei   +5 more
openaire   +4 more sources

Molecular mechanisms of cisplatin resistance [PDF]

Oncogene, 2011
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi, L, Senovilla, I, Vitale, J, Michels, I, Martins, O, Kepp, M, Castedo, G, Kroemer   +7 more
openaire   +2 more sources

Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum

Jurnal Kesehatan, 2020
Cisplatin is a type of platinum-based chemotherapy that is often used in the spectrum of solid neoplasms, including the ovaries, testicles, urinary vesicles, colorectal, lungs, and head-neck.
Amelia Rizky Khalidah
doaj   +1 more source

Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1

iScience, 2023
Summary: Cisplatin resistance remains a major obstacle limiting the effectiveness of chemotherapy in cervical cancer. However, the underlying mechanism of cisplatin resistance is still unclear.
Xiangyu Tan, Xueqian Wang, Xueyao Liao, Xin Wang, Zhichao Jiang, Wenjia Liang, Chen Cao, Danni Gong, Zheng Hu, Xun Tian   +9 more
doaj   +1 more source

Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]

PLoS ONE, 2014
Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj   +1 more source

TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway

Nature Communications, 2023
Cisplatin resistance along with chemotherapy-induced neuropathic pain is an important cause of treatment failure for many cancer types and represents an unmet clinical need.
Se Jin Oh, Ji Yeon Lim, Min Kyu Son, Jun Hyeok Ahn, Kwon-Ho Song, Hyo-Jung Lee, Suyeon Kim, Eun Ho Cho, Joon-Yong Chung, Hanbyoul Cho, Hyosun Kim, Jae-Hoon Kim, Jooyoung Park, Jungmin Choi, Sun Wook Hwang, Tae Woo Kim   +15 more
doaj   +1 more source

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

Thoracic Cancer, 2021
Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in ...
Minghui Liu, Liyuan Cui, Xin Li, Chunqiu Xia, Yongwen Li, Rui Wang, Fan Ren, Hongyu Liu, Jun Chen   +8 more
doaj   +1 more source

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han   +18 more
doaj   +1 more source